STOCKSCREENR

0RA9.L

LSE

Abivax S.A.

$92.20-0.55(-0.59%)Mkt Cap: $7.30B

Key Stats

Market Cap

$7.30B

P/E Ratio

-37.33

EPS

$-2.47

Dividend Yield

0.00%

52-Week Range

$5.68 — $94.50

Volume

72.23K

Avg Volume

5.41K

Beta

-0.10

Price Alerts for 0RA9.L

Get alerted when 0RA9.L hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-37.33

Forward P/E

—

PEG Ratio

0.39

P/S (TTM)

0.00

P/B (TTM)

16.14

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-1.65%

ROA (TTM)

-0.58%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.07

Current Ratio

8.75

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.02%

EPS Growth (5Y)

-0.03%

Sales Growth (3Y)

+41.40%

Sales Growth (5Y)

+25.77%

EPS Est (This Year)

$-3.04

EPS Est (Next Year)

$-2.69

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$7.63

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

77.83M

Float

62.55M

Free Float %

80.37%

About

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

FR

Exchange

LSE

IPO Date

2016-09-30

Employees

69

CEO

Marc de Garidel

Index Membership

—

Website

https://www.abivax.com

Abivax S.A. (0RA9.L) is a healthcare company in the medical - pharmaceuticals industry listed on the LSE. With a market capitalization of $7.30B, a P/E ratio of -37.33, 0RA9.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare 0RA9.L against other stocks using dozens of fundamental and technical filters.

Similar Stocks

0RU5.L

Oncoinvent ASA

$49.50

+3.13%

$1.94B

0J2O.L

Halozyme Therapeutics, Inc.

$64.11

+1.60%

$7.57B

0RD1.L

Camurus AB (publ)

$530.55

+0.06%

$31.64B

0JAV.L

Insmed Incorporated

$136.55

+1.81%

$29.44B

0JDM.L

IQVIA Holdings Inc.

$158.90

+1.74%

$26.97B

0K10.L

Mettler-Toledo International Inc.

$1268.78

+0.86%

$26.15B

Frequently Asked Questions

What is Abivax S.A.'s P/E ratio?

Abivax S.A. (0RA9.L) has a trailing twelve-month (TTM) P/E ratio of -37.33. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Abivax S.A. pay a dividend?

No, Abivax S.A. (0RA9.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Abivax S.A.'s market cap?

Abivax S.A. (0RA9.L) has a market capitalization of $7.30 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.